COMP <GO>
MDGL vs UNH // ENTERPRISE SCALE & MARKET CAP
Madrigal Pharmaceuticals Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: MDGL 3
— UNH 9
▲ ENTERPRISE SCALE & MARKET CAP LEADER: UNH
LAST: $431.16 (+0.19%) • MKT CAP: $9.96B
market-cap
$9.96B
LAST: $400.44 (-1.60%) • MKT CAP: $359.43B
market-cap
$359.43B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MDGL VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MDGL | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 88.31% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -29.70% | 12.38% | -42.08 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.91% | 6.25% | -8.16 | UNH | /fcf-yield <GO> |
| Operating Margin | -31.30% | 5.32% | -36.62 | UNH | /operating-margins <GO> |
| Net Profit Margin | -30.10% | 3.53% | -33.63 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 3.33% | +176.67 | MDGL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.29% | -2.29 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.65 | 3.09 | +4.56 | MDGL | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 7.00% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 30.8 | 55.1 | -24.30 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 0.33 | +0.75 | MDGL | /macro-sensitivity <GO> |
| Forward P/E Multiple | 24.0x | 17.7x | +6.26 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $9.96B | $359.43B | -$349.47B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MDGL REV | UNH REV | MDGL GROSS % | UNH GROSS % | MDGL FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $958.4M | $447.57B | — | 88.7% | -$190.0M | $16.07B |
| FY 2024 | $180.1M | $400.28B | 96.5% | 88.3% | -$457.0M | $20.70B |
| FY 2023 | $1.07B | $371.62B | — | 89.6% | -$324.2M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MDGL // BETA 1.08
UNH // BETA 0.33